Abstract
INTRODUCTION: A group of primary bone tumors called chondrosarcomas are diverse and characterized by neoplastic tissue of hyaline cartilage. They are the second most typical primary osseous cancer. Recurrence is indicative of a poor prognosis because traditional chondrosarcomas are resistant to treatment. Our knowledge of the pathobiology of conventional chondrosarcomas has greatly expanded owing to recent findings in these tumors' biology, genetics, and epigenetics studies. These findings also provide information on possible treatment targets. CHEK2 encodes a checkpoint kinase involved in DNA damage response and cell cycle regulation, and it is an important cancer susceptibility gene. METHODS: The Gene2 drug and DSEA assisted with in silico screening. The antitumor activities of the candidate drugs were extracted from DepMap via the PRISM viability assay on eight chondrosarcoma cell lines. RESULTS AND CONCLUSION: Advances in studies show promise for discovering potential targeted treatments for cancer. Bisacodyl is a targeted G protein-coupled receptor 35. G protein-coupled receptors are widely known targets for cancer treatment. Here, we showed that bisacodyl can be a potential therapeutic agent in chondrosarcoma cell lines.